We developed an integrated biomarker development approach that harnessed evidence from controlled in vitro experiments with ER+/HER2- breast cancer cell lines treated with everolimus and combined this with data from a neoadjuvant clinical trial of ER+ breast cancer patients treated with everolimus. Here, ERBB2 is linked to breast carcinoma.